Journal article
Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011
Abstract
BACKGROUND: In 1995, a publicly funded pneumococcal vaccination program for 23-valent polysaccharide vaccine (PPV23) was introduced in Ontario. Conjugate vaccines were authorized in 2001 (PCV7), 2009 (PCV10) and 2010 (PCV13).
METHODS: From 1995-2011, active, population-based surveillance for invasive pneumococcal disease (IPD) was conducted in Metropolitan Toronto and Peel Region, Canada.
Authors
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I
Journal
Vaccine, Vol. 31, No. 49, pp. 5863–5871
Publisher
Elsevier
Publication Date
December 2013
DOI
10.1016/j.vaccine.2013.09.049
ISSN
0264-410X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAge DistributionAgedAged, 80 and overChildChild, PreschoolCost of IllnessFemaleHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ProgramsIncidenceInfantInfant, NewbornMaleMiddle AgedOntarioPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillanceVaccines, ConjugateYoung Adult